Clemens Zwergel

Pubblicazioni

Titolo Pubblicato in Anno
PD-L1 small-molecule modulators: a new hope in epigenetic-based multidrug cancer therapy? DRUG DISCOVERY TODAY 2022
Restoration of WT1/miR-769-5p axis by HDAC1 inhibition promotes MMT reversal in mesenchymal-like mesothelial cells CELL DEATH & DISEASE 2022
Novel pyridine-containing histone deacetylase inhibitors strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2022
Selenium-Containing Agents Acting on Cancer—A New Hope? PHARMACEUTICS 2022
Amphetamine modulation of long-term object recognition memory in rats: influence of stress FRONTIERS IN PHARMACOLOGY 2021
Sirtuins Encyclopedia of Molecular Pharmacology 2021
Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2–EED Interaction JOURNAL OF MEDICINAL CHEMISTRY 2021
m6A RNA methylation and beyond - the epigenetic machinery and potential treatment options DRUG DISCOVERY TODAY 2021
Polycomb repressive complex 2 modulation through the development of EZH2–EED interaction inhibitors and EED binders JOURNAL OF MEDICINAL CHEMISTRY 2021
Sex-dependent effects of the drugs of abuse amphetamine and the smart drug 3,4-methylenedioxypyrovalerone on fear memory generalization in rats NEUROSCIENCE 2021
Novel quinoline compounds active in cancer cells through coupled DNA methyltransferase inhibition and degradation CANCERS 2020
Tranylcypromine-based LSD1 inhibitors: structure-activity relationships, antiproliferative effects in leukemia, and gene target modulation CHEMMEDCHEM 2020
Sirtuin modulators: where are we now? A review of patents from 2015 to 2019 EXPERT OPINION ON THERAPEUTIC PATENTS 2020
Discovery of the first human arylsulfatase a reversible inhibitor impairing mouse oocyte fertilization ACS CHEMICAL BIOLOGY 2020
Design of first-in-class dual EZH2/HDAC inhibitor: biochemical activity and biological evaluation in cancer cells ACS MEDICINAL CHEMISTRY LETTERS 2020
Discovery of phenylselenoether-hydantoin hybrids as ABCB1 efflux pump modulating agents with cytotoxic and antiproliferative actions in resistant T-lymphoma EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2020
Detrimental effects of the 'bath salt' methylenedioxypyrovalerone on social play behavior in male rats NEUROPSYCHOPHARMACOLOGY 2020
The innovative potential of statins in cancer: new targets for new therapies FRONTIERS IN CHEMISTRY 2020
Editorial: chemical innovative approaches in cancer molecular medicine and translational clinical research FRONTIERS IN CHEMISTRY 2020
Novel Pyridine-Based Hydroxamates and 2'-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity CHEMMEDCHEM 2020

ERC

  • LS1_13

KET

  • Life-science technologies & biotechnologies

Interessi di ricerca

Dr. Clemens Zwergel is currently an Assistant Professor (RTD-A) at the Sapienza University of Rome. In the last years he proved to be a true European citizen: he moved after his license to practise as Pharmacist from his country of origin (Germany) to Exter (UK) for a Diploma in Pharmaceutical Sciences. Before moving to Italy, he was then a MarieCurie fellow in France (Metz) where he obtained his EuroPhD within the RedCat network. Since 2010, his main research interest lies mainly in the design and synthesis of analogues of natural compounds as well as modulators of epigenetic enzymes with potential applications in cancer, neurodegenerative, metabolic, and infectious diseases resulting in more than 70 publications (https://www.scopus.com/authid/detail.uri?authorId=37017859900). Communication and divulging science are very important aspects for a researcher, thus I would like to increase the visibility of Medicinal Chemistry and the EFMC to the scientific community as well as the general public as well as strengthen the European collaborations together with the other team members.

Keywords

medicinal chemistry

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma